Evofem Biosciences' GAAP loss for 9M 2021 was $153.638 million, up 51.1% from $101.711 million in the previous year. Revenue increased 16.8 times to $4.674 million from $0.278 million a year earlier.
Evofem Biosciences' GAAP loss for 9M 2021 was $153.638 million, up 51.1% from $101.711 million in the previous year. Revenue increased 16.8 times to $4.674 million from $0.278 million a year earlier. 
evofem.investorroom.com
English (US) 